Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Rilematovir in Hepatic Impairment
NCT04332523Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rilematovir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration and 1 more. Started Aug 2020; status: terminated.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04332523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332523.